LUND, SWEDEN, April 8, 2020 /PRNewswire/ -- Immunovia AB (publ)
("Immunovia") today announced that the company's Lung Cancer
collaboration with a global pharmaceutical company has been
terminated.
Immunovia's own early detection program in lung cancer continues
as planned and the company has received the necessary fresh blood
samples from the pharma partner for testing and analysis.
Immunovia's study is on track and will be finished in Q2 2020 as
planned.
This is information that Immunovia is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person
set out above, at 8:45 CET on
April 8, 2020.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently entering the final validation for sales start Q3
2020. When validated, IMMray™ PanCan-d will be the first
blood-based test for early diagnosis of pancreatic cancer on the
market, with a potential to significantly improve patient survival
and outcome.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
For more information, please contact:
Julie Silber
Director of Investor Relations
Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-and-global-pharmaceutical-company-agree-on-early-termination-of-lung-cancer-collaboration,c3084106
The following files are available for download:
https://mb.cision.com/Main/13121/3084106/1226623.pdf
|
Release
|
View original
content:http://www.prnewswire.com/news-releases/immunovia-and-global-pharmaceutical-company-agree-on-early-termination-of-lung-cancer-collaboration-301037308.html
SOURCE Immunovia AB